Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A Phase 1/2 study of the menin inhibitor revumenib with the celmod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias

View Full Paper
Ask AI
Bookmark
Share

Authors

KCKuo‐Kai ChinADAndriy DerkachJZJoshua F. Zeidner

Discussion

Loading...

Member takes

Overview

Phase 1/2 trial tests revumenib and mezigdomide in relapsed/refractory acute leukemias, indicating potential for improved outcomes.

Key Points

  • To evaluate the combination of revumenib and mezigdomide in treating relapsed or refractory KMT2A, NPM1, and NUP98 rearranged acute leukemias.
  • Phase 1/2, multicenter, investigator-initiated trial
  • Participants include MENIN inhibitor refractory and naïve patients
  • Utilizes a 3+3 dose escalation design to determine maximum tolerated dose
  • Primary endpoint focuses on safety and tolerability
  • Includes two cohorts: MENINi-naïve and MENINi-exposed.
  • Designed to establish maximum tolerated dose of revumenib with mezigdomide
  • Evaluates depth and duration of response
  • Monitors for immunomodulatory effects
  • Targets improved CR/CRh rates in both cohorts
  • Study funded and IRB-approved with anticipated patient accrual in 2025.

Cite This Study

Chin et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3adhttps://doi.org/10.1182/blood-2025-1657
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study2025 · 1 citations
  2. 2A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed <i>NPM1</i> -mutated acute myeloid leukemia (REVEAL-ND NPM1).2026 · 1 citations
  3. 3Efficacy and Potential Limitation of the Menin Inhibitor Revumenib Outside Clinical Trials: Extramedullary Response with Central Nervous System Escape in a Case of KMT2A-Rearranged Acute Myeloid Leukemia2026
  4. 4A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed <i>NPM1</i> -mutated or <i>KMT2A</i> -rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002).2026 · 1 citations
  5. 5Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms2025